PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma. - Kim DH; Koh J; Ahn JS; Moon J; Kang M; Park G; Lim Y; Ock CY; Jeon YK; Jung KC; Ahn SH; Chung EJ; et al. (Oral surgery, oral medicine, oral pathology and oral radiology, 2026)